Tenofovir Disoproxil Market Report 2026

Tenofovir Disoproxil Market Overview

• Tenofovir Disoproxil market size has reached to $3.76 billion in 2025 • Expected to grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Rising Hepatitis B Cases Fuel Demand For Antiviral Treatment • Market Trend: Global Quality Certified Formulations Expand Access and Drive Tenofovir Disoproxil Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tenofovir Disoproxil Market?

Tenofovir disoproxil is a medication used to treat HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it transforms into its active form in the body, preventing viruses from replicating. It falls under the nucleotide reverse transcriptase inhibitors (NRTIs) class, which block a key enzyme necessary for viral multiplication. The main types of tenofovir disoproxil are tablet and powder. A tablet is a solid medicinal form compressed into a small, easy-to-swallow shape, designed to dissolve in the digestive system to release the active ingredient either gradually or immediately. The distribution channels include online pharmacies, retail pharmacies, and wholesalers or distributors and finds applications are in hospitals and clinics.

What Is The Tenofovir Disoproxil Market Growth Forecast?

The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising demand for chronic viral management, expansion of generic antiviral production, increasing healthcare access in emerging markets, growth in preventive antiviral use, sustained public health funding. Major trends in the forecast period include rising demand for antiviral combination therapies, increased use in hiv and hepatitis b management, growing adoption of fixed-dose combinations, expansion of long-term antiviral treatment, increased focus on viral suppression strategies.

Global Tenofovir Disoproxil Market Segmentation

1) By Type: Tablet, Powder 2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Wholesalers Or Distributors 3) By Application: Hospital, Clinic Subsegments: 1) By Tablet: Single-Drug Tablets, Fixed-Dose Combination Tablets 2) By Powder: Oral Powder, Reconstitutable Powder

What Are The Drivers Of The Tenofovir Disoproxil Market?

The growing prevalence of hepatitis B is expected to fuel the growth of the tenofovir disoproxil market going forward. Hepatitis B is a viral infection that attacks the liver, potentially causing both acute and chronic disease, and is transmitted through contact with infected blood or bodily fluids. The growing prevalence of hepatitis B is driven by factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations. Tenofovir disoproxil is used in the treatment of chronic hepatitis B to suppress viral replication and reduce liver damage. For instance, in March 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based government agency for protecting public health, in the United States, an estimated 580,000 to 2.4 million people are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Therefore, the growing prevalence of hepatitis B is driving the growth of the tenofovir disoproxil industry. The rising healthcare expenditure is expected to propel the growth of the tenofovir disoproxil market going forward. Healthcare expenditure refers to the total financial resources spent on medical goods and services to maintain and improve population health. Healthcare expenditure is rising because an aging population requires more frequent medical care and long-term health services. Higher healthcare expenditure supports the uptake of tenofovir disoproxil by enabling broader access to antiviral therapies, improving diagnosis and treatment rates, and strengthening healthcare systems’ capacity to manage chronic hepatitis B and HIV. For instance, in April 2025, according to the Office for National Statistics, a UK-based government department, between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms, and by 2.4% in real terms after accounting for inflation. Therefore, the rising healthcare expenditure is expected to propel the growth of the tenofovir disoproxil industry.

Key Players In The Global Tenofovir Disoproxil Market

Major companies operating in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Mylan N.V., Qilu Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Hetero Drugs Limited, Laurus Labs Limited, Zydus Lifesciences Ltd., Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd., Arene Lifesciences, Aurisco Pharmaceutical Co. Ltd., Sinoway Industrial Co. Ltd.

Global Tenofovir Disoproxil Market Trends and Insights

Major companies operating in the tenofovir disoproxil market are focusing on expanding access via international quality certified formulations, such as WHO prequalified tablets, to reach global HIV and hepatitis B patient populations. A WHO prequalified tenofovir disoproxil fumarate tablet meets rigorous global standards for quality, safety, and efficacy, enabling broader distribution in resource limited settings. For instance, in August 2024, Shijiazhuang Lonzeal Pharmaceuticals Co., Ltd., a China based pharmaceutical company, achieved WHO prequalification for its 300 mg tenofovir disoproxil fumarate 300 mg film coated tablet (Product code HP030), with demonstrated bioequivalence, GMP certification, and acceptability for HIV treatment. Therefore, global quality certified supply is driving the growth of the tenofovir disoproxil market.

Regional Insights

North America was the largest region in the tenofovir disoproxil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tenofovir Disoproxil Market?

The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tenofovir Disoproxil Market Report 2026?

The tenofovir disoproxil market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.